In a new study, researchers from the University of California, Los Angeles, identified lung cancer cells using a protein called SGLT2 (sodium glucose transporter 2, sodium glucose transporter 2). glucose. This finding provides evidence that SGLT2 may be a novel biomarker that scientists may use to aid in the diagnosis of precancerous lung disease and early stage lung cancer. The results of the study were published in the November 14, 2018 issue of Science Translational Medicine, entitled "Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma".
Cancer cells need a lot of glucose to survive and grow. Past research has determined that the protein GLUT (glucose transporter) is the primary means by which the body delivers glucose to tumors. However, more recent studies have found that some cancers, such as prostate and pancreatic cancer, also rely on SGLT2 to utilize glucose, which prompted researchers from the University of California, Los Angeles to study the role of SGLT2 in lung cancer.
It is necessary to find an earlier method for diagnosing lung cancer when it is easier to treat because it is currently the leading cause of cancer-related deaths in men and women worldwide.
These researchers used positron emission tomography (PET) to capture SGLT activity in lung cancer cells. They were able to use SGLT2 activity to monitor the efficacy of SGLT2 inhibitors in a mouse model of hereditary lung cancer and in mice implanted with human lung tumors .
These researchers found abnormally high levels of SGLT2 in human lung cancer specimens, suggesting that these lung tumors primarily use SGLT2 instead of GLUT to transport glucose during early growth stages, even in precancerous lesions prior to lung cancer.
This study suggests that people may be able to detect lung cancer earlier when it is easier to treat. By using SGLT2 as a biomarker, it is not only possible to find lung cancer earlier than it is currently, but it may even be found before a precancerous lesion develops cancer. The researchers also provided evidence that as a commonly used SGLT2 inhibitor drug approved by the US FDA, a net-type drug (currently used to treat diabetes) may help block SGLT2 activity in cancer cells. Listed drugs may be used to block glucose uptake and help reduce tumor growth.
Reference materials:
Claudio R. Scafoglio1,*, Brendon Villegas1, Gihad Abdelhady et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Science Translational Medicine, 14 November 2018, 10(467):eaat5933, doi: 10.1126/scitranslmed.aat5933.
AAA) YANMAR DIESEL ENGINE
K(D)L, KFL-T, 6MAL-H/T/HT/DT, S165-T/ST/EN,
S185-ST/UT/ET, M200L-UN/SN/EN/M220L-UN/SN/EN / N 330
BBB) DAIHATSU DIESEL ENGINE
PS22/26/ DS18(A)/ DS(B)22/
DL20/22/28/ DK20 / DK 28
CCC) NIIGATA DIESEL ENGINE
6L(M)25BX/6M28AFTE/BX/6M31X/EZ/EX/ 31AFTE /34AGT
DDD) AKASAKA
AH30/AH38/ AH40/D/F/ A31/34/37/41/ DM28/30/33/36/38/40(A)K/ DM46/ UEC37H-HB/ UEC 37/88H
UEC 37LA/ UEC45LA/ UEC52LA/ UEC52HA/ UEC60HA/ UEC60LS/ UEC45HA/115 ALL UET TYPE
EEE) MITSUBISHI (KOBE AND AKASAKA )
45/75C/ 45/80D/ 52/90D/ 52/105D.E/
UEC37H-IIB/ UET37/88HA/UEC45HA.LA/ UEC52HA.LA/ S6B/
ETC
FFF) HANSHIN
6LU(D)26/ 6LU(N)28A/ 6LU(D)32/6LU(D)35/ 6LU(S)38/ 40 / 6LU40/ 6LU46A/ 6LU50A/
6EL30/ EL(S)32 /6EL(S)35/ 6EL38/ 6EL40/ 6EL(S)44/50A/
GGG) MAN B&W
S35MC/L35MCE/L50MCE/ L60MCE/ 40/54A
HHH) MITSUBISHI PURIFIER
SJ700~SJ1800/SJ 2000
III)SULZER
RND 68 RND 76 RD 44
JJJ) MAKITA
GSLH – 633 637 KSLH -633 637
Kkk) PIELSTICK
PC 2-5 PC 2-6